> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.8% Of Iovance — The Cancer-Therapy Company's Sales Outpace Last Year
- URL: https://www.bullished.co/state-street-holds-4-8-of-iovance-the-cancer-therapy-companys-sales-outpace-last-year-8a93f13b/
- Published: 2026-11-10T13:47:53.000Z
- Updated: 2026-11-10T13:47:53.000Z
- Description: The passive position covered 21,695,003 shares, while Iovance's third-quarter net loss narrowed to $22.3 million.
- Author: Matteo Parrino
- Tags: SEC Filings, IOVA, Industry: Healthcare

State Street reported a [4.8% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000677/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Iovance Biotherapeutics](https://www.bullished.co/tag/iova/), which develops and sells cell therapies for solid tumor cancers, in a passive ownership disclosure filed Tuesday. The position covered 21,695,003 shares as of September 30, against a backdrop of rising revenue and smaller losses at the cancer-treatment company.

## Sales Improved, Shares Fell

Iovance reported third-quarter [revenue of $121.5 million](https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-iova-q3-earnings-061311741.html?.tsrc=rss&ref=bullished.co), compared with $67.5 million a year earlier. Its net loss narrowed to $22.3 million from $91.3 million.

The company attributed sales growth to Amtagvi and Proleukin. Amtagvi contributed about $102 million of quarterly revenue, and Iovance reiterated its full-year revenue forecast of $410 million to $420 million.

The stock's performance told a different story: IOVA shares fell about 38% over the 30 days before the third-quarter report. Bailey Pemberton wrote in Yahoo Finance commentary that investors had been [disappointed after Amtagvi's](https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-iova-q3-earnings-061311741.html?.tsrc=rss&ref=bullished.co) 2025 commercial launch.

Iovance's market value was $3.8 billion as of 8:45 a.m. ET Tuesday.

## A Passive Position, Not A Control Bid

State Street certified that the shares were held through [ordinary business activity](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000677/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co), rather than for the purpose or effect of changing or influencing Iovance's control.

The reported stake uses the disclosure's beneficial-ownership basis. State Street listed shared voting power over 20,523,410 shares and shared power to dispose of 21,695,003 shares.

## Treatment Built From Patients' Immune Cells

Iovance's tumor infiltrating lymphocyte therapy uses each patient's own immune cells. Amtagvi is an individualized, one-time T cell treatment for adults with previously treated advanced melanoma, approved in the United States and Canada and administered through authorized treatment centers.

Its other commercial product, Proleukin, is an interleukin-2 drug used in the Amtagvi regimen and other applications. Iovance produces its cell therapies at its Philadelphia, Pennsylvania, manufacturing center; its research pipeline includes lung cancer and melanoma trials.

State Street's disclosure records a passive ownership position while Iovance works toward its reiterated full-year sales forecast.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: IOVANCE BIOTHERAPEUTICS INC (IOVA)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000677/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More](https://finance.yahoo.com/markets/stocks/articles/barclays-deutsche-bank-reveal-stakes-083352520.html?ref=bullished.co) — Yahoo Finance
- [Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery](https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-iova-q3-earnings-061311741.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on Iovance Biotherapeutics

- [Iovance Reaches About $122 Million In Quarterly Sales While Cutting Its Loss](https://www.bullished.co/iovance-reaches-about-122-million-in-quarterly-sales-while-cutting-its-loss-e75b9207/)
- [Iovance Lung Cancer Therapy Shows 24.6% Response Rate In Updated Data, With FDA Filing Planned For 2027](https://www.bullished.co/iovance-lung-cancer-therapy-shows-24-6-response-rate-in-updated-data-with-fda-filing-846ae05f/)
- [Iovance Stock Plunges 12%, Wiping Out $525 Million, After Lung Cancer Data Draws Questions](https://www.bullished.co/iovance-stock-plunges-12-wiping-out-525-million-after-lung-cancer-data-draws-questions-9f7f1d6d/)

[All Iovance Biotherapeutics (IOVA) coverage →](https://www.bullished.co/tag/iova/)